Skip to main content
LPCN
NASDAQ Life Sciences

Director Higuchi Buys 150,000 LPCN Shares for $225,225 on the Open Market

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.44
Mkt Cap
$16.389M
52W Low
$1.36
52W High
$12.37
52W Position info
5.9% above low
Off High info
88% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

LPCN is trading near its 52-week low of $1.36 (5.9% above the low) on light trading volume (0.1× avg).

Summary

Director John Higuchi bought 150,000 Lipocine shares for $225,225 at $1.49-$1.51 on November 19-20, raising his direct holdings to 391,365 shares. It is his largest purchase yet and follows a CEO buy earlier in November.


Key Events · Ownership and Investor Activity · LPCN

  • Director Buys 150,000 Shares

    John Higuchi purchased 150,000 shares on the open market for $225,225 across two trades on November 19-20, 2026, at $1.49-$1.51 per share.

  • Stake Rises to 391,365 Shares

    Post-transaction direct holdings stand at 391,365 shares, up from 241,365 after his early-October purchases.

  • Largest Buy in the Series

    The $225,225 total is about four times his October 2 purchase of $55,043 and roughly eight times his October 1 purchase of $27,132.

  • Insider Accumulation Continues

    Follows the CEO's 50,000-share open-market buy on November 12-13 for $79,487.50; the 90-day open-market tally shows $161,662 of net buying and no insider sales.


Analysis · LPCN · Life Sciences

Director John Higuchi put $225,225 of his own money into Lipocine across two open-market purchases at $1.49-$1.51, lifting his direct stake to 391,365 shares. That is roughly four times the size of his early-October buys and comes as the stock trades near the level of those purchases, so it reads as continued conviction rather than a one-off. It also extends a broader insider accumulation pattern: the CEO bought 50,000 shares on November 12-13, and the 90-day open-market tally now shows $161,662 of net buying with no insider sales.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LPCN was trading at $1.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.4M. The 52-week trading range was $1.36 to $12.37. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LPCN - Latest Insights

LPCN
Nov 13, 2026, 3:23 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $1.69
Real-time Price: $1.52 info
Change: -$0.170 (-10%) info
Market Cap: $16.389M info
LPCN
Nov 05, 2026, 9:30 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.47
Real-time Price: $1.52 info
Change: +$0.050 (+3%) info
Market Cap: $16.389M info
LPCN
Nov 05, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.45
Real-time Price: $1.52 info
Change: +$0.070 (+5%) info
Market Cap: $16.389M info
LPCN
Oct 07, 2026, 6:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.16
Real-time Price: $1.52 info
Change: -$0.640 (-30%) info
Market Cap: $16.389M info
LPCN
Sep 14, 2026, 6:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.27
Real-time Price: $1.52 info
Change: -$0.750 (-33%) info
Market Cap: $16.389M info